The product plays a role in managing chronic wounds which may be difficult to heal. It is commonly used to help with the management of specific, severe conditions, including full-thickness diabetic foot ulcers that are typically greater than six weeks in duration.

Dermagraft is primarily applied in clinical settings that involve acute or unstable symptom patterns and is relevant for managing symptom clusters that create noticeable physiological strain on the body's healing mechanisms. The core benefit plays a role in managing the wound base, which assists with eventual closure. It is applied to support tissue repair and may assist with reaching sustained wound closure in challenging scenarios where standard care has stalled.

As an adjunctive therapy, Dermagraft is reserved for high-risk patients, mainly adults with diabetes, whose condition may hinder their ability to heal. This approach may assist with maintaining functional stability and supports general well-being during symptomatic periods.

---

Quick Fact: Relief for Stalled Ulceration

The product is applied in addressing conditions marked by increased discomfort or tension, specifically for chronic, non-healing ulcers that have entered a stalled state and may require additional symptomatic support.

Regulatory References

1. U.S. FDA Premarket Approval

Eligibility Scope

Dermagraft is officially indicated for adult patients (18 years or older) with full-thickness diabetic foot ulcers that have persisted for greater than six weeks and require use in conjunction with standard wound care regimens.

---

Contraindicated Populations

Official regulatory labeling establishes absolute restrictions for several patient groups. Dermagraft is contraindicated for use in individuals with a known hypersensitivity to bovine products, as the manufacturing and storage medium may contain trace bovine proteins. It must not be used on ulcers that show signs of clinical infection, contain sinus tracts (tunnels), or extend into deep structures such as the tendon, muscle, joint capsule, or bone.

---

Use Restrictions and Limitations

Classification	Rule (Based on Regulatory Documents)
Pediatric Use	Use has not been studied in children under the age of 18 years.
Pregnancy/Lactation	Use has not been studied in pregnant women. Eligibility status during lactation is not explicitly documented.
Comorbidity Status	Not studied in patients receiving corticosteroids or immunosuppressive agents, or in patients with ulcers over a Charcot deformity of the mid-foot.
Vascular Status	Use requires that patients have adequate blood supply to the involved foot to support healing.

Interactions with other medicines and products

The regulatory profile for Dermagraft focuses primarily on constraints related to concurrent local wound care and the lack of clinical data with certain systemic medications. These constraints are vital for maintaining the product's integrity and ensuring optimal performance.

Documented Interaction Precautions

Interacting Product Category	Interaction Mechanism & Outcome	Regulatory Constraint
Topical Agents (Lotions, Ointments, Creams, Gels)	May cause reduced viability of the Dermagraft product.	Do not use any topical agents, cytotoxic cleansing solutions, or medications directly on an ulcer being treated with Dermagraft.
Cytotoxic Cleansing Solutions	May cause reduced viability of the Dermagraft product.	Do not use any topical agents, cytotoxic cleansing solutions, or medications directly on an ulcer being treated with Dermagraft.

Populations Not Studied

Clinical studies have not evaluated the use of Dermagraft in patients who are concurrently receiving certain systemic treatments. This represents an information gap regarding potential interactions, rather than a definitive contraindication or safety signal.

• Systemic Agents Not Studied: The product has not been studied in patients receiving corticosteroids, immunosuppressive agents, or cytotoxic agents.

Patients or healthcare providers should adhere strictly to the usage guidelines, as the application of topical preparations directly to the treated ulcer is the most significant documented interaction concern for this product.

Active Signal Generation and Paracrine Action

The mechanism initiates when the viable human fibroblast cells within the product act as a localized bioreactor, continuously secreting essential biological components like Growth Factors (e.g., VEGF, KGF) and Cytokines. This process, known as paracrine signaling, engages specific Growth Factor Receptors on host endothelial cells and fibroblasts, thereby stimulating the Angiogenesis and Cell Proliferation Pathways to shift the local microenvironmental balance toward tissue synthesis and organization.

Structural Scaffolding and Dermal Restoration

Concurrently, the bioabsorbable matrix provides a three-dimensional template, while the fibroblasts deposit newly synthesized Extracellular Matrix (ECM) proteins, particularly Human Dermal Collagen. This dual action physically addresses the structural deficit and counteracts the activity of Matrix Metalloproteinases (MMPs)—enzymes that break down matrix components—by influencing the local environment toward synthesis. This physiological effect guides the migration and proliferation of host cells, facilitating the formation of robust, vascularized granulation tissue (neodermis), which supports the organization of the re-established dermal structure.

Mechanistic Dependence and Constraints

The entire regenerative cascade is critically dependent on the survival and metabolic activity of the allogeneic fibroblasts, which drives the continuous signal generation. The product's action is localized and requires adequate host vascular supply and responsive native cells for the secreted factors to exert their full physiological effect and for the new granulation tissue to undergo proper development and organization.

Administration Protocol

The administration of Dermagraft is strictly topical, involving the application of the cryopreserved human fibroblast-derived dermal substitute directly onto the prepared ulcer surface. The procedure is intended for use in adults with specific full-thickness diabetic foot ulcers, requiring the patient to have adequate blood supply to the involved foot. The product is designated for prescription use and is applied as an adjunctive component of standard wound care, which must include wound bed debridement and pressure off-loading.

Usage Constraint	Official Specification
Dosing Unit	One single piece of the dermal substitute (5 cm x 7.5 cm) per session.
Frequency Pattern	Applied typically once per week.
Course Duration	The regimen may continue for up to 8 applications in total.
Handling Time Limit	The product must be used within 30 minutes of thawing and rinsing.

Procedural Requirements

Proper use mandates specific handling of the cryopreserved product: it must first be thawed and rinsed according to procedural guidelines prior to placement on the wound. This ensures the delivery of metabolically active cells. Following the topical application of the piece, the wound and its dressing should not be disturbed for at least 72 hours to allow for initial cellular integration and attachment. The treatment sequence is primarily defined by the weekly frequency and the total limit of applications.

Research Evidence: Overview of Studies for Dermagraft

---

Evidence for Use in Chronic Diabetic Foot Ulcers

Research examining Dermagraft was studied for full-thickness diabetic foot ulcers (DFUs) that have been present for six weeks or longer and are considered chronic. These studies were generally structured as Randomized Controlled Trials (RCTs), where patients were assigned by chance to receive either Dermagraft plus standard wound care, or standard care alone. This design was used to explore patterns in measured outcomes between the two groups over a defined period.

The main measurements tracked in these trials related to the achievement of full epithelialization. Specifically, research examined the percentage of patients in each group who achieved complete healing by a pre-set time, most commonly 12 weeks. Studies also monitored the time required for the wound surface to close entirely. Research describes patterns observed in these short-term closure outcomes when Dermagraft was evaluated alongside standard care in this specific context.

---

Defining the Population Studied in Trials

The results from the primary regulatory studies apply only to the populations studied. The research focused strictly on adults with Type 1 or Type 2 Diabetes Mellitus who had ulcers that were confirmed to be chronic. Patients were carefully selected to exclude those with active clinical infections, exposed bone, muscle, or tendon, or signs of gangrene. The research focused on wounds under specific physiological conditions; data derived from patients with more complex or unstable cases are limited because those patients were generally excluded from the trials.

---

Long-Term Follow-up and Durability Studies

While the primary measurements of epithelialization were typically tracked over a short-term period of about 12 weeks, some research has explored longer-term outcomes. These extended studies monitored patients for up to nearly two years (ranging from 11 to 22 months) after their wound had initially closed. The intent of these long-term observational settings explored patterns in the recurrence of the ulcer in the same site. However, comprehensive, consistently reported data on these long-term outcomes are not fully established across all published studies, contributing to the broader evidence landscape but with limited long-term information.

---

What Remains Uncertain in the Research Landscape

The overall research provides insight into short-term changes, but methodological consistency varies across studies, and evidence remains limited regarding some outcomes. One recognized methodological limitation is the inability to perform a double-blind study. Additionally, the results apply only to the highly selected populations studied, and the follow-up durations were limited.

Key Studies & References Biologic skin substitutes: current status and challenges

How to Store and Dispose of Dermagraft?

Because Dermagraft contains viable cells in a cryopreserved form, storage and handling requirements are highly specific and mandatory, as defined by official labeling.

Mandatory Storage Conditions

Dermagraft must be stored continuously in the frozen state at -75 C pm 10 C (mathbf-85 C to mathbf-65 C) until it is ready for use, according to U.S. FDA requirements. The product must not be refrozen, reused, or sterilized.

Handling and Stability Rules

Once thawed and prepared, the product has an extremely limited time for use: it must be applied or discarded within 30 minutes at room temperature. Handling precautions require avoiding skin and eye contact with the cryoprotectant solution, which contains 10% Dimethylsulfoxide (DMSO).

Disposal Requirements

Any unused, expired, or compromised product must be discarded. Disposal of Dermagraft must adhere strictly to local regulations for biological waste due to its composition as human tissue.